122 related articles for article (PubMed ID: 14726189)
21. [In vitro diagnostic medical devices--the legal context].
Látal T
Klin Mikrobiol Infekc Lek; 2009 Dec; 15(6):196-200. PubMed ID: 20077396
[TBL] [Abstract][Full Text] [Related]
22. Rapid Diagnostic Tests for Neglected Infectious Diseases: Case Study Highlights Need for Customer Awareness and Postmarket Surveillance.
Barbé B; Verdonck K; El-Safi S; Khanal B; Teav S; Lilo Kalo JR; Ravinetto R; Chappuis F; Boelaert M; Jacobs J
PLoS Negl Trop Dis; 2016 Nov; 10(11):e0004655. PubMed ID: 27812099
[No Abstract] [Full Text] [Related]
23. Sterile by any other name.
Donawa ME
Med Device Technol; 1996; 7(1):12-5. PubMed ID: 10172722
[TBL] [Abstract][Full Text] [Related]
24. Fake drugs: lessons for the world. Dora Akunyili interviewed by Meredith Wadman.
Akunyili D
Nature; 2008 Apr; 452(7190):924. PubMed ID: 18441547
[No Abstract] [Full Text] [Related]
25. Uncertainty on trial.
Callaway E
Nature; 2013 Oct; 502(7469):17-8. PubMed ID: 24091960
[No Abstract] [Full Text] [Related]
26. The in vitro diagnostic directive countdown.
Place JF
Med Device Technol; 1999; 10(1):44. PubMed ID: 10344873
[No Abstract] [Full Text] [Related]
27. New countermeasures considered as drug counterfeiting grows.
Schubert C
Nat Med; 2008 Jul; 14(7):700. PubMed ID: 18607355
[No Abstract] [Full Text] [Related]
28. Amendments to the medical device directive.
Cutler IR
Med Device Technol; 1996; 7(1):24-7. PubMed ID: 10172723
[TBL] [Abstract][Full Text] [Related]
29. Myths, beliefs and fragrance allergy.
Contact Dermatitis; 2013 Oct; 69(4):193-5. PubMed ID: 24028782
[No Abstract] [Full Text] [Related]
30. Substandard and counterfeit medicines.
Rassool GH
J Adv Nurs; 2004 May; 46(3):338-9. PubMed ID: 15119344
[No Abstract] [Full Text] [Related]
31. The essential element of ethics.
Donawa ME
Med Device Technol; 2004 Jun; 15(5):27-9. PubMed ID: 15285485
[TBL] [Abstract][Full Text] [Related]
32. Behringwerke anti-HIV test kits.
Becker W
Lancet; 1989 Aug; 2(8660):458-9. PubMed ID: 2569647
[No Abstract] [Full Text] [Related]
33. Regulatory challenges for in vitro diagnostics in a global environment.
Longwell A
Qual Assur; 1994 Jun; 3(2):167-77. PubMed ID: 7804632
[TBL] [Abstract][Full Text] [Related]
34. US and European postmarket clinical data requirements.
Donawa M
Med Device Technol; 2005 Mar; 16(2):19-21. PubMed ID: 15828495
[TBL] [Abstract][Full Text] [Related]
35. [Reliability of clinical diagnosis using a kit based on immunochromatography method].
Inano K
Rinsho Byori; 2007 Jan; Suppl 138():57-63. PubMed ID: 17477128
[No Abstract] [Full Text] [Related]
36. Health hazard labeling for hazard communication in the pharmaceutical industry.
Sussman RG; Kimmel TA; Neske FW
Occup Med; 1997; 12(1):107-17. PubMed ID: 9153056
[TBL] [Abstract][Full Text] [Related]
37. Beyond the US submisson process.
Donawa M
Med Device Technol; 2004 Apr; 15(3):30-2. PubMed ID: 15255536
[TBL] [Abstract][Full Text] [Related]
38. Johnson & Johnson to pay $2.2bn to settle charges of false marketing on three drugs.
Kmietowicz Z
BMJ; 2013 Nov; 347():f6696. PubMed ID: 24196512
[No Abstract] [Full Text] [Related]
39. Safe use of art materials: who is responsible?
Gottsegen M
Environ Health Perspect; 1997 Jul; 105(7):687-8. PubMed ID: 9294708
[No Abstract] [Full Text] [Related]
40. [Expected change of direction in Polish law regarding cosmetics].
Karłowski K; Smietanka B; Biernat U; Burzyńska I; Pawłowska K
Rocz Panstw Zakl Hig; 2004; 55(1):21-5. PubMed ID: 15307612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
